CHEK2 mutation-associated breast tumors are more likely to be estrogen receptor (ER)-positive than sporadic breast cancers, and patients with breast cancer who carry a CHEK2 mutation respond well to tamoxifen [51,52,53,54]. This evidence concerns the gene ESR1 and breast cancer.